Literature DB >> 29407054

Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.

Dragana Lovre1, Sulay Shah2, Aanu Sihota2, Vivian A Fonseca3.   

Abstract

We discuss mechanisms of increased cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) and strategies for managing cardiovascular (CV) risk in these patients. Our focus was mainly on decreasing CV events and progression of microvascular complications by reducing levels of glucose and lipids. We searched PubMed with no limit on the date of the article. All articles were discussed among all authors. We chose pertinent articles, and searched their references in turn for additional relevant publications.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  A1C; Cardiovascular risk factors; Chronic kidney disease; Diabetes mellitus; Dyslipidemia of chronic kidney disease; Fructosamine; Glycated albumin

Mesh：

Substances：

Year:  2017        PMID： 29407054      PMCID： PMC5806139          DOI： 10.1016/j.ecl.2017.10.006

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN： 0889-8529            Impact factor:   4.741


  118 in total

1.  Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection.

Authors:  Masaaki Inaba; Senji Okuno; Yasuro Kumeda; Shinsuke Yamada; Yasuo Imanishi; Tsutomu Tabata; Mikio Okamura; Shigeki Okada; Tomoyuki Yamakawa; Eiji Ishimura; Yoshiki Nishizawa
Journal:  J Am Soc Nephrol       Date:  2007-01-31       Impact factor: 10.121

2.  Blood glucose fluctuations in hemodialysis patients with end stage diabetic nephropathy.

Authors:  Yue-ping Jin; Xiao-fei Su; Guo-ping Yin; Xiao-hua Xu; Ji-zhuang Lou; Jian-jun Chen; Yue Zhou; Jie Lan; Bing Jiang; Zheng Li; Kok-Onn Lee; Lei Ye; Jian-hua Ma
Journal:  J Diabetes Complications       Date:  2014-12-31       Impact factor: 2.852

3.  Specific glycation of albumin depends on its half-life.

Authors:  E D Schleicher; B Olgemöller; E Wiedenmann; K D Gerbitz
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

4.  What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis?

Authors:  H Ichikawa; Y Nagake; M Takahashi; H Nakazono; K Kawabata; K Shikata; H Makino
Journal:  Nihon Jinzo Gakkai Shi       Date:  1996-07

5.  Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4.

Authors:  Harn-Shen Chen; Tzu-En Wu; Hong-Da Lin; Tjin-Shing Jap; Li-Chuan Hsiao; Shen-Hung Lee; Shu-Hsia Lin
Journal:  Am J Kidney Dis       Date:  2010-03-03       Impact factor: 8.860

6.  ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages.

Authors:  J F Oram; R M Lawn; M R Garvin; D P Wade
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

7.  Serum albumin-adjusted glycated albumin reflects glycemic excursion in diabetic patients with severe chronic kidney disease not treated with dialysis.

Authors:  Kei Fukami; Ryo Shibata; Hitomi Nakayama; Kentaro Yamada; Seiya Okuda; Masafumi Koga
Journal:  J Diabetes Complications       Date:  2015-06-16       Impact factor: 2.852

8.  Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial.

Authors:  Girish N Nadkarni; Veena Rao; Faramarz Ismail-Beigi; Vivian A Fonseca; Sudhir V Shah; Michael S Simonson; Lloyd Cantley; Prasad Devarajan; Chirag R Parikh; Steven G Coca
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-17       Impact factor: 8.237

9.  The estimation of serum fructosamine: an alternative measurement to glycated haemoglobin.

Authors:  E J Hindle; G M Rostron; J A Gatt
Journal:  Ann Clin Biochem       Date:  1985-01       Impact factor: 2.057

10.  Comparison of reliability of plasma fructosamine and glycosylated hemoglobin assays for assessing glycemic control in diabetic patients on hemodialysis.

Authors:  K Nunoi; T Kodama; Y Sato; M Iwase; H Yoshizumi; H Kurimoto; H Nishitani; S Nakamura; M Fujishima
Journal:  Metabolism       Date:  1991-09       Impact factor: 8.694
View more
  4 in total

1.  Addressing Diabetes and Poorly Controlled Hypertension: Pragmatic mHealth Self-Management Intervention.

Authors:  Allison A Lewinski; Uptal D Patel; Clarissa J Diamantidis; Megan Oakes; Khaula Baloch; Matthew J Crowley; Jonathan Wilson; Jane Pendergast; Holly Biola; L Ebony Boulware; Hayden B Bosworth
Journal:  J Med Internet Res       Date:  2019-04-09       Impact factor: 5.428

2.  Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial.

Authors:  Thomas R Pieber; Harpreet S Bajaj; Simon R Heller; Ting Jia; Kamlesh Khunti; David C Klonoff; Steen Ladelund; Lawrence A Leiter; Lily Wagner; Athena Philis-Tsimikas
Journal:  Diabetes Obes Metab       Date:  2021-10-17       Impact factor: 6.408

Review 3.  Diabetic patients with chronic kidney disease: Non-invasive assessment of cardiovascular risk.

Authors:  Nejc Piko; Sebastjan Bevc; Robert Ekart; Tadej Petreski; Nina Vodošek Hojs; Radovan Hojs
Journal:  World J Diabetes       Date:  2021-07-15

4.  Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.

Authors:  Rajiv Agarwal; Stefan D Anker; George Bakris; Gerasimos Filippatos; Bertram Pitt; Peter Rossing; Luis Ruilope; Martin Gebel; Peter Kolkhof; Christina Nowack; Amer Joseph
Journal:  Nephrol Dial Transplant       Date:  2022-05-25       Impact factor: 7.186
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.